US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Perspective Therapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Perspective Therapeutics to Participate at Upcoming Investor Conferences in August
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces $87.4 Million Private Placement
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Participate at Upcoming Investor Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Proposed Public Offering
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Divests Brachytherapy Business
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT-α-NET by Clinical Collaborators in Germany
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Completes Initial Dose Escalation Cohort for Second Novel Targeted Alpha Therapy
From Perspective Therapeutics, Inc.
Via GlobeNewswire
News headline image
Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT-α-NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors
From Perspective Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >